Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell
lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or
by presence of biomarkers associated with the anti-tumor effects of Rituximab.